GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (STU:7UM) » Definitions » Price-to-Owner-Earnings

Ultimovacs ASA (STU:7UM) Price-to-Owner-Earnings : (As of Jun. 14, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ultimovacs ASA Price-to-Owner-Earnings?

As of today (2024-06-14), Ultimovacs ASA's share price is €0.697. Ultimovacs ASA does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Ultimovacs ASA's Price-to-Owner-Earnings or its related term are showing as below:


STU:7UM's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.65
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-14), Ultimovacs ASA's share price is €0.697. Ultimovacs ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.45. Therefore, Ultimovacs ASA's PE Ratio for today is At Loss.

As of today (2024-06-14), Ultimovacs ASA's share price is €0.697. Ultimovacs ASA's EPS without NRI for the trailing twelve months (TTM) ended in was €-0.45. Therefore, Ultimovacs ASA's PE Ratio without NRI for today is At Loss.


Ultimovacs ASA Price-to-Owner-Earnings Historical Data

The historical data trend for Ultimovacs ASA's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Price-to-Owner-Earnings Chart

Ultimovacs ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only - - - - -

Ultimovacs ASA Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ultimovacs ASA's Price-to-Owner-Earnings

For the Biotechnology subindustry, Ultimovacs ASA's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultimovacs ASA's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultimovacs ASA's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Ultimovacs ASA's Price-to-Owner-Earnings falls into.



Ultimovacs ASA Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Ultimovacs ASA's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.697/-0.47
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ultimovacs ASA  (STU:7UM) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Ultimovacs ASA Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Ultimovacs ASA's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultimovacs ASA (STU:7UM) Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, 0379
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Ultimovacs ASA (STU:7UM) Headlines

No Headlines